These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 8123737)

  • 1. Estimation of impurity profiles in drugs and related materials. Part 11--The role of chromatographic and spectroscopic methods in the estimation of side-reactions in drug syntheses.
    Görög S; Balogh G; Csehi A; Csizér E; Gazdag M; Halmos Z; Hegedüs B; Herényi B; Horváth P; Laukó A
    J Pharm Biomed Anal; 1993; 11(11-12):1219-26. PubMed ID: 8123737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estimation of impurity profiles of drugs and related materials: part XXI. HPLC/UV/MS study of the impurity profile of ethynodiol diacetate.
    Babják M; Balogh G; Gazdag M; Görög S
    J Pharm Biomed Anal; 2002 Aug; 29(6):1153-7. PubMed ID: 12110402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estimation of impurity profiles of drugs and related materials: part 19: theme with variations. Identification of impurities in 3-oxosteroids.
    Görög S; Babják M; Balogh G; Brlik J; Dravecz F; Gazdag M; Horváth P; Laukó A; Varga K
    J Pharm Biomed Anal; 1998 Dec; 18(4-5):511-25. PubMed ID: 9919951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimation of impurity profiles of drugs and related materials. 12. Isolation and identification of an isomeric impurity in danazol.
    Balogh G; Csizér E; Ferenczy GG; Halmos Z; Herényi B; Horváth P; Laukó A; Görög S
    Pharm Res; 1995 Feb; 12(2):295-8. PubMed ID: 7784348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimation of impurity profiles of drugs and related materials. Part VIII: Combined application of high-performance liquid chromatography and NMR spectroscopy in the impurity profiling of drugs.
    Görög S; Balogh G; Gazdag M
    J Pharm Biomed Anal; 1991; 9(10-12):829-33. PubMed ID: 1668302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Forced degradation and impurity profiling: recent trends in analytical perspectives.
    Jain D; Basniwal PK
    J Pharm Biomed Anal; 2013 Dec; 86():11-35. PubMed ID: 23969330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Estimation of impurity profiles of drugs and related materials. 20. Methodological problems in the identification and determination of organic impurities].
    Görög S
    Acta Pharm Hung; 2000; 70(3-6):131-7. PubMed ID: 11379019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemical and analytical characterization of related organic impurities in drugs.
    Görög S
    Anal Bioanal Chem; 2003 Nov; 377(5):852-62. PubMed ID: 12937879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estimation of impurity profiles of drugs and related materials. Part 9: HPLC investigation of flumecinol.
    Görög S; Herényi B; Rényei M
    J Pharm Biomed Anal; 1992; 10(10-12):831-5. PubMed ID: 1298390
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimation of impurity profiles of drugs and related materials. Part 14: the role of HPLC/diode-array UV spectroscopy in the identification of minor components (impurities, degradation products, metabolites) in various matrices.
    Görög S; Bihari M; Csizér E; Dravetz F; Gazdag M; Herényi B
    J Pharm Biomed Anal; 1995 Dec; 14(1-2):85-92. PubMed ID: 8833970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification, isolation and characterization of process related impurities in ezetimibe.
    Guntupalli S; Ray UK; Murali N; Gupta PB; Kumar VJ; Satheesh D; Islam A
    J Pharm Biomed Anal; 2014 Jan; 88():385-90. PubMed ID: 24176742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methodological problems in drug interactions.
    Mulé SJ
    Ann N Y Acad Sci; 1976; 281():106-17. PubMed ID: 798518
    [No Abstract]   [Full Text] [Related]  

  • 13. Development of Impurity Profiling Methods Using Modern Analytical Techniques.
    Ramachandra B
    Crit Rev Anal Chem; 2017 Jan; 47(1):24-36. PubMed ID: 27070830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Use of spectroscopic methods in drug analysis].
    Spiteller G
    Arzneimittelforschung; 1975 Jul; 25(7a):1140-8. PubMed ID: 1242343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification, isolation, characterization and response factor determination of process-related impurity in meprobamate drug substance.
    Karthikeyan K; Arularasu GT; Murali V; Pillai KC
    J Pharm Biomed Anal; 2011 Jan; 54(1):208-12. PubMed ID: 20727702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estimation of impurity profiles of drugs and related materials Part 18. Impurities and degradation products of mazipredone.
    Gazdag M; Babják M; Brlik J; Mahó S; Tuba Z; Görög S
    J Pharm Biomed Anal; 1998 Sep; 17(6-7):1029-36. PubMed ID: 9884192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of a street drug as N-ethyl-1-phenylcyclohexylamine, a phencyclidine analog.
    Bailey K
    J Pharm Sci; 1978 Jun; 67(6):885-6. PubMed ID: 660485
    [No Abstract]   [Full Text] [Related]  

  • 18. Drug impurity profiling strategies.
    Görög S; Babják M; Balogh G; Brlik J; Csehi A; Dravecz F; Gasdag M; Horváth P; Laukó A; Varga K
    Talanta; 1997 Sep; 44(9):1517-26. PubMed ID: 18966892
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impurities in illicit amphetamine: review.
    Sinnema A; Verweij AM
    Bull Narc; 1981; 33(3):37-54. PubMed ID: 7039749
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Automated peak tracking for comprehensive impurity profiling in orthogonal liquid chromatographic separation using mass spectrometric detection.
    Xue G; Bendick AD; Chen R; Sekulic SS
    J Chromatogr A; 2004 Oct; 1050(2):159-71. PubMed ID: 15508308
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.